Caution in Interpreting <i>NOTCH1</i> Mutation as a Predictive Biomarker of Tislelizumab Response in Esophageal Squamous Cell Carcinoma

Zhimeng Lu

Zhimeng Lu, MD, and Kun Yan, MD, Department of Cardiothoracic Surgery, The Affiliated Jiangyin Hospital of Nantong University, Wuxi, China; Yifang Sheng, MD, Jiangyin Clinical College of Xuzhou Medical University, Wuxi, China; Praise Audax Rukonge, MD, Department of Cardiothoracic Surgery, Jiangyin Clinical College of Xuzhou Medical University, Wuxi, China; and Zhonghua Qin, MD, Zhe Zhang, MD, and Guiping Yu, MD, Department of Cardiothoracic Surgery, The Affiliated Jiangyin Hospital of Nantong University, Wuxi, China

Kun Yan

Yifang Sheng

Zhimeng Lu, MD, and Kun Yan, MD, Department of Cardiothoracic Surgery, The Affiliated Jiangyin Hospital of Nantong University, Wuxi, China; Yifang Sheng, MD, Jiangyin Clinical College of Xuzhou Medical University, Wuxi, China; Praise Audax Rukonge, MD, Department of Cardiothoracic Surgery, Jiangyin Clinical College of Xuzhou Medical University, Wuxi, China; and Zhonghua Qin, MD, Zhe Zhang, MD, and Guiping Yu, MD, Department of Cardiothoracic Surgery, The Affiliated Jiangyin Hospital of Nantong University, Wuxi, China

Praise Audax Rukonge

Zhimeng Lu, MD, and Kun Yan, MD, Department of Cardiothoracic Surgery, The Affiliated Jiangyin Hospital of Nantong University, Wuxi, China; Yifang Sheng, MD, Jiangyin Clinical College of Xuzhou Medical University, Wuxi, China; Praise Audax Rukonge, MD, Department of Cardiothoracic Surgery, Jiangyin Clinical College of Xuzhou Medical University, Wuxi, China; and Zhonghua Qin, MD, Zhe Zhang, MD, and Guiping Yu, MD, Department of Cardiothoracic Surgery, The Affiliated Jiangyin Hospital of Nantong University, Wuxi, China

Zhonghua Qin

Zhe Zhang

Guiping Yu